Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Radiol. 2012 Sep 28;4(9):405-12.

Embolization of liver tumors: Past, present and future.

Author information

  • 1Ashwin Rammohan, Jeswanth Sathyanesan, Anand Lakshmanan, Perumal Senthil-Kumar, Ulagendra Perumal Srinivasan, Ravi Ramasamy, Palaniappan Ravichandran, The Institute of Surgical Gastroenterology and Liver Transplantation, Centre for GI Bleed, Division of HPB Diseases, Stanley Medical College Hospital, Chennai 600001, India.

Abstract

Curative therapies for hepatocellular carcinoma (HCC), such as resection and liver transplantation, can only be applied in selected patients with early tumors. More advanced stages require local or systemic therapies. Resection of HCC offers the only hope for cure. Even in patients undergoing resection, recurrences are common. Chemoembolization, a technique combining intra-arterial chemotherapy with selective tumor ischemia, has been shown by randomized controlled trials to be efficacious in the palliative setting. There is now renewed interest in transarterial embolization/transarterial chemoembolization (TACE) with regards to its use as a palliative tool in a combined modality approach, as a neoadjuvant therapy, in bridging therapy before transplantation, for symptomatic indications, and even as an alternative to resection. There have also been rapid advances in the agents being embolized trans-arterially (genes, biological response modifiers, etc.). The current review provides an evidence-based overview of the past, present and future trends of TACE in patients with HCC.

KEYWORDS:

Chemoembolization; Embolization; Liver tumors; Review

PMID:
23024842
PMCID:
PMC3460228
DOI:
10.4329/wjr.v4.i9.405
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center